**Supplemental Digital Content 3. Per-Participant Composite Microbiologic and Clinical Response at EOIV, EOT, and TOC Visits (mMITT Population)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **EOIV** | | **EOT** | | **TOC** | |
|  | **C/T (N=71)** | **MEM**  **(N=24)** | **C/T (N=71)** | **MEM**  **(N=24)** | **C/T (N=71)** | **MEM**  **(N=24)** |
| Success, n (%) | 65 (91.5) | 24 (100.0) | 63 (88.7) | 23 (95.8) | 57 (80.3) | 21 (87.5) |

C/T, ceftolozane/tazobactam; EOIV, end of intravenous therapy; EOT, end of treatment; MEM, meropenem; mMITT, microbiologic modified intent to treat; TOC, test of cure.